Almirall Acquires Veltin® and Altabax® from Stiefel, a GSK Company


Almirall has acquired the rights to  Veltin® and Altabax, from Stiefel, a GSK company, in exchange for  distribution rights to Toctino® and an undisclosed cash payment.


In June 2010, Barcelona-based Almirall signed a distribution agreement with Basilea Pharmaceutica Ltd (Basilea) for Toctino®, granting Almirall commercialisation rights in selected European markets and Mexico. Stiefel acquired worldwide rights to Toctino® in June 2012 from Basilea, and has now consolidated rights to Toctino® in Europe. Altabax® is a patent protected and novel topical treatment for impetigo. Veltin® is a prescription antibiotic indicated for the topical treatment of acne, the largest Dermatology indication in the US with a total market size of approximately $3 billion.

Both Veltin® and Altabax® will be commercialised through Almirall’s US affiliate, Aqua Pharmaceuticals. 

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free